source
- FDA lifts opposition to Huntington’s disease gene therapy, clearing path for developmentThe Readout Loud podcast this week highlighted a regulatory shift for a gene therapy aimed at Huntington’s disease. The Food and Drug Administration reversed its earlier opposition, removing a key…
- Eli Lilly stops 340B discounts for dozens of hospitals that did not submit claims dataEli Lilly has begun removing the federally mandated 340B price discounts for a few dozen hospitals that have not provided the required claims data. The company said the step follows a warning it is…